RXRX Recursion Pharmaceuticals, Inc.
$3.16
Recursion Pharmaceuticals, Inc. (RXRX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Insider signal
In line
Selling ran in line with RXRX's own trailing one-year pace, with 93% of sale value under a prearranged plan.
Cluster activity
0 buyers in the last 30 days
0 buyers in the last 90 days
3 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
5
36 transactions
Purchases
$0
0 shares
Sales
$8.9M
2,129,811 shares
Net activity
-$8.9M
purchases less sales
How much of that selling was preplanned? 93% planned / 7% discretionary
10b5-1 plan sales
$8.3M
35 transactions · 1,959,811 shares
Discretionary sales
$588.2K
1 transaction · 170,000 shares
Largest single sale: $961.4K.
Where they traded
Buy
Sell
Dot area is proportional to transaction value.
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Khan Najat | CEO and President | Sell 10b5-1 | 22,408 | $3.52 | $78.8K | 2,072,890 −1.1% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 30,000 | $3.34 | $100.2K | 6,158,287 −0.5% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 30,000 | $3.25 | $97.5K | 6,188,287 −0.5% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 40,000 | $3.96 | $158.5K | 6,218,287 −0.6% of holding | |
| Bumpus Namandje | Director | Sell 10b5-1 | 3,963 | $3.18 | $12.6K | 127,632 −3% of holding | |
| Gibson Christopher | Director | Sell 10b5-1 | 40,000 | $3.62 | $144.8K | 883,735 −4.3% of holding | |
| Khan Najat | CEO and President | Sell 10b5-1 | 23,588 | $3.58 | $84.5K | 2,175,796 −1.1% of holding | |
| Bumpus Namandje | Director | Sell 10b5-1 | 4,386 | $3.54 | $15.5K | 43,171 −9.2% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 30,000 | $3.68 | $110.4K | 6,169,863 −0.5% of holding | |
| Gibson Christopher | Director | Sell 10b5-1 | 40,000 | $3.08 | $123.2K | 883,735 −4.3% of holding | |
| Gibson Christopher | Director | Sell 10b5-1 | 40,000 | $3.37 | $134.8K | 926,556 −4.1% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 30,000 | $3.52 | $105.6K | 6,199,863 −0.5% of holding | |
| Gibson Christopher | Director | Sell 10b5-1 | 40,000 | $3.61 | $144.4K | 906,556 −4.2% of holding | |
| Gibson Christopher | Director | Sell 10b5-1 | 40,000 | $3.10 | $124.0K | 906,556 −4.2% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 30,000 | $3.10 | $93.0K | 6,229,863 −0.5% of holding | |
| Gibson Christopher | Director | Sell 10b5-1 | 40,000 | $3.25 | $130.0K | 906,556 −4.2% of holding | |
| Taylor Ben R | Chief Financial Officer | Sell 10b5-1 | 7,956 | $3.39 | $27.0K | 1,180,318 −0.7% of holding | |
| Khan Najat | CEO and President | Sell 10b5-1 | 28,298 | $3.35 | $94.7K | 2,262,085 −1.2% of holding | |
| Borgeson Blake | Director | Sell | 170,000 | $3.46 | $588.2K | 6,259,863 −2.6% of holding | |
| Gibson Christopher | Director | Sell 10b5-1 | 40,000 | $3.46 | $138.4K | 906,556 −4.2% of holding | |
| Taylor Ben R | Chief Financial Officer | Sell 10b5-1 | 13,426 | $3.08 | $41.4K | 1,195,349 −1.1% of holding | |
| Gibson Christopher | Director | Sell 10b5-1 | 40,000 | $4.12 | $164.8K | 913,839 −4.2% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 220,000 | $4.20 | $924.0K | 6,429,863 −3.3% of holding | |
| Gibson Christopher | Director | Sell 10b5-1 | 40,000 | $4.47 | $178.8K | 913,839 −4.2% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 220,000 | $4.36 | $959.2K | 6,649,863 −3.2% of holding | |
| Gibson Christopher | Director | Sell 10b5-1 | 40,000 | $4.25 | $170.0K | 933,839 −4.1% of holding | |
| Taylor Ben R | Chief Financial Officer | Sell 10b5-1 | 21,383 | $4.18 | $89.4K | 761,550 −2.7% of holding | |
| Khan Najat | Chief R&D Commercial Officer | Sell 10b5-1 | 124,403 | $4.41 | $548.6K | 611,135 −16.9% of holding | |
| Gibson Christopher | Chief Executive Officer | Sell 10b5-1 | 40,000 | $4.50 | $180.0K | 913,839 −4.2% of holding | |
| Gibson Christopher | Chief Executive Officer | Sell 10b5-1 | 40,000 | $4.63 | $185.2K | 933,839 −4.1% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 220,000 | $4.37 | $961.4K | 6,869,863 −3.1% of holding | |
| Gibson Christopher | Chief Executive Officer | Sell 10b5-1 | 40,000 | $4.16 | $166.4K | 913,839 −4.2% of holding | |
| Gibson Christopher | Chief Executive Officer | Sell 10b5-1 | 40,000 | $5.21 | $208.4K | 974,229 −3.9% of holding | |
| Gibson Christopher | Chief Executive Officer | Sell 10b5-1 | 100,000 | $5.70 | $570.0K | 954,229 −9.5% of holding | |
| Gibson Christopher | Chief Executive Officer | Sell 10b5-1 | 100,000 | $6.04 | $604.0K | 974,229 −9.3% of holding | |
| Gibson Christopher | Chief Executive Officer | Sell 10b5-1 | 100,000 | $4.76 | $476.0K | 954,229 −9.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.